ReviewInternational journal of molecular sciences2026
Balancing Ubiquitination and Deubiquitination in Apoptotic Protein Stability and Cancer Cell Survival.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Programmed cell death is essential for maintaining cellular homeostasis, and its evasion is a defining hallmark of cancer. The threshold for apoptosis is largely determined by the stability of pro- and anti-apoptotic proteins, which is tightly regulated by the ubiquitin-proteasome system (UPS). In this system, E1, E2, and E3 enzymes sequentially attach ubiquitin chains that mark substrates for degradation by the 26S proteasome, whereas deubiquitinating enzymes (DUBs) reverse these modifications to stabilize specific substrates. The opposing actions of E3 ubiquitin ligases and DUBs therefore form a dynamic network that fine-tunes the abundance of key apoptotic regulators and ultimately determines cell survival or death. In this review, we summarize how DUBs control the stability of central components of both the intrinsic and extrinsic apoptotic pathways, including the p53 pathway, BCL-2 family proteins such as MCL-1, and anti-apoptotic regulators including cellular FLICE-like inhibitory protein (c-FLIP) and inhibitor of apoptosis proteins (IAPs). We also discuss how linkage-specific ubiquitin editing at death receptor complexes influences the balance between survival and apoptosis. Finally, we discuss how dysregulation of DUB-mediated protein stability promotes apoptotic evasion in cancer and highlight the therapeutic potential of DUB-targeted strategies, including catalytic inhibitors and stabilization approaches such as deubiquitinase-targeting chimeras (DUBTACs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.